Quotient Clinical, a translational pharmaceutics company, began its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program. RapidFACT was developed in 2008 with the goal of transforming the process of optimizing drug product formulations. According to the company, this service has now been proven to accelerate program timelines by at least 50% and reduce costs. Quotient’s translational pharmaceutics platform incorporates realtime GMP manufacturing and clinical testing, which enables formulation selection to be supported by emerging clinical data.
RapidFACT has been deployed in early development and life cycle management programs to develop oral, inhaled, dermal and ocular drug products. These programs have focused on optimizing drug products for once- or twice-daily dosing, or addressing poor solubility.
Mark Egerton, chief executive officer of Quotient Clinical, said, "RapidFACT was launched in response to the challenges our customers told us they were confronting in their development programs. We are pleased that the potential benefits we identified in 2008 have translated into real timeline reductions and cost savings in all of our RapidFACT programs. Ultimately, this approach is helping our customers to address many of the R&D productivity issues prevalent in the industry today."
Quotient Clinical Begins 50th RapidFACT Program
By Kristin Brooks
Published February 6, 2014
blog comments powered by Disqus